Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants
Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants
Researchers in this study want to learn about the safety of drug BAY1817080 at different
 doses and the resulting blood levels of the study drug in Japanese healthy adult male
 participants. Study drug BAY1817080 is a drug under development with a goal to suppress pain
 and chronic cough. It works by binding to and blocking proteins expressed on the sensory
 nerves of the womb tissue, bladder or airway which are oversensitive in the patients with
 endometriosis (a condition where the tissue that usually grows inside the womb grows outside
 of the womb), overactive bladder (a condition that causes a sudden urge to urinate often or
 more frequently) and long-standing cough with or without clear causes.

 Participants in this study will receive either the study drug or placebo tablets (a placebo
 looks like the test drug but does not have any medicine in it). The dosage will be either one
 single dose of study drug/placebo received on only one day or multiple doses of study
 drug/placebo received twice daily for 13 days plus one dose in the morning of the 14th day.
 The total study duration for each participant will be usually no more than 42 days. Blood
 samples will be collected from the participants to monitor the safety and measure the blood
 level of the study drug.
Inclusion Criteria:

 -  Participant must be 20 to 45 years of age inclusive, at the time of signing the
 informed consent.

 -  Participants who are overtly healthy as determined by medical evaluation including
 medical history, physical examination, vital signs, laboratory tests, and ECG.

 -  Non-smoker for at least 6 months and with a pack year history of equal to or less than
 5 years

 -  Race: Japanese.

 -  BMI: above or equal 18.0 and below or equal 30.0 kg/m² at the screening visit.

 -  Contraceptive use should be consistent with local regulations regarding the methods of
 contraception for those participating in clinical studies.

 -  Men of reproductive potential must agree to use adequate contraception when sexually
 active. This applies for the time period between signing of the ICF and 90 days after
 the last administration of study intervention.

 Exclusion Criteria:

 -  Any findings from the medical examination (including medical history, physical
 examination, vital signs, laboratory tests and ECG) deviating from normal and deemed
 by the investigator to be of clinical relevance

 -  Relevant diseases potentially interfering with the study objectives within the 4 weeks
 before screening or between screening and randomization

 -  Any febrile illness within the four weeks before screening or between screening and
 randomization

 -  Any known presence or history of severe allergies, non-allergic drug reactions, or
 multiple drug allergies

 -  Known or suspected malignant tumors or carcinoma in situ

 -  Any history of malignant tumors

 -  Any known or suspected benign tumors of the liver and/or pituitary gland

 -  Known liver disease: existing acute or chronic progressive liver disease, e.g.
 disturbance of bilirubin excretion (Dubin-Johnson and Rotor syndromes); disturbances
 of bile secretion and flow (cholestasis); presence or history of liver tumors (benign
 or malignant). Note: According to this criterion there must have been an interval of
 at least 6 months between the subsidence of any viral hepatitis (normalization of
 liver parameters) and the screening visit.